recognized as an important potential therapeutic target for cancer. Six series of 3(5)-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)pyrazoles (11a-d, 12a-d, and 18a-d) and 3(5)-(6-methylpyridin-2-yl)-4-(2-phenyl-pyridin-4-yl)pyrazoles (19a-d, 20a-d, and 21a-d) were synthesized and evaluated for activin receptor-like kinase 5 (ALK5) and HIF-1α inhibitory activity at the enzyme and cell levels. The effect of
                                    转录因子缺氧诱导因子-1α(HIF-1α)在细胞凋亡,转移和增殖中起着重要作用,并且被认为是重要的潜在癌症治疗靶标。六个系列的3(5)-(6-
甲基吡啶-2-基)-4-(
喹啉-4-基)
吡唑(11a-d,12a-d和18a-d)和3(5)-(6合成了-
甲基吡啶-2-基)-4-(
2-苯基吡啶-4-基)
吡唑(19a-d,20a-d和21a-d)并评估了激活素受体样激酶5(ALK5)和HIF-1α在酶和细胞
水平的抑制活性。研究了
铅化合物20d(J-1012)对HCT116细胞中HIF-1α活化的影响。J-1012剂量依赖性地显着降低了缺氧诱导或TNF诱导的HIF-1α蛋白积累。分析表明,J-1012抑制了HIF-1α蛋白质的合成,而没有影响HIF-1α蛋白质的降解。此外,通过抑制HIF-1α的活化,J-1012抑制了HCT116细胞的转移和增殖,并促进了HCT116细胞的凋亡。这些结果表明,J-1012可能是抗人类结肠癌的潜在治疗剂。